Study:
A Phase II Study of Concurrent Chemoradiotherapy Using Three-Dimensional Conformal Radiotherapy (3D-CRT) or Intensity-Modulated Radiation Therapy (IMRT) + Bevacizumab (BV) for Locally or Regionally Advanced Nasopharyngeal Cancer
Rationale:
Monoclonal antibodies, such as bevacizumab, can block tumor growth in different
ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and
help kill them or carry tumor-killing substances to them. Bevacizumab may also stop the
growth of nasopharyngeal cancer by blocking blood flow to the tumor. Drugs used in
chemotherapy, such as cisplatin and fluorouracil, work in different ways to stop the growth
of tumor cells, either by killing the cells or by stopping them from dividing. Radiation
therapy uses high-energy x-rays to kill tumor cells. Giving bevacizumab together with
chemotherapy and radiation therapy may kill more tumor cells.
Purpose:
This phase II trial is studying how well giving bevacizumab together with
cisplatin, radiation therapy, and fluorouracil works in treating patients with stage IIB,
stage III, stage IVA, or stage IVB nasopharyngeal cancer.
Study Status: Completed
Recruiting:
n/a
| Condition |
Intervention |
Phase |
|
Head and Neck Cancer |
Biological: bevacizumab
Drug: cisplatin
Drug: fluorouracil
Procedure: adjuvant therapy
Radiation: 3-dimensional conformal radiation therapy
Radiation: intensity-modulated radiation therapy |
Phase 2 |
Verified by
Radiation Therapy Oncology Group
June, 2009
Sponsored by: Radiation Therapy Oncology Group
Information provided by: National Cancer Institute (NCI)
ClinicalTrials.gov identifier: NCT00408694
Study Type: Interventional
Study Design: Masking: Open Label, Primary Purpose: Treatment
Cleveland Clinic Taussig Cancer Center
Cleveland, Ohio 44195
United States
Nancy Lee, MD., Principal Investigator